ClinicalTrials.gov
public full text
Public Domain
DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
This study aimed to investigate the efficacy and safety of DEP (liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for EBV associated hemophagocytic lymphohistiocytosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.#288709
- Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia#874072
- Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types#863388
- Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study#883954
- Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39(+)CD8(+) T cells highlights immunotherapy-resistant features in NSCLC.#323041
Record · ID 811308
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive